New pill could bring relief to eczema sufferers
NCT ID NCT07180511
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial is testing an experimental oral drug called QY201 in 460 adults with moderate to severe atopic dermatitis (eczema). Participants will take either QY201 or a placebo daily for 16 weeks. The main goals are to see if the drug can significantly clear the skin and reduce the severity of the condition. The study is currently enrolling by invitation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QY201 tablet
What this could lead to
If successful, this could provide a new oral treatment option for people with moderate to severe atopic dermatitis, helping to clear skin and reduce itching.
What could go wrong
This is still an experimental drug in Phase 3 testing. It may not work better than placebo, and side effects are possible. Results are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EnitiateBioPharma
Hangzhou, Zhejiang, China